Who is affected by this change?

This affects Independence Blue Cross Hematology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective Dec 19, 2025.

Back to dashboard

CommercialCoverageLow impact

08.02.15, Lovotibeglogene autotemcel (Lyfgenia®)

Independence Blue Cross·Hematology, Oncology·Pharmacy

Effective date

Dec 19, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX has reissued policy 08.02.15 for Lovotibeglogene autotemcel (Lyfgenia®), a gene therapy medication. This is an updated commercial pharmacy policy that will take effect December 19, 2025, with specific coverage criteria for this specialized treatment.

Action Required

Action needed

By December 19, 2025: Review updated Lyfgenia® coverage policy on IBX provider portal. If practice treats patients requiring gene therapy, verify current prior authorization requirements and coverage criteria. Most practices will not be affected as this is a highly specialized gene therapy medication.

Related policy hubs

Independence Blue Cross policies Hematology Oncology